Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04494243
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT04489797
- Locations
- 🇺🇸
Research Site, Anaheim, California, United States
A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
- Conditions
- Duodenal Ulcer，DU
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Target Recruit Count
- 448
- Registration Number
- NCT04215653
Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT04211545
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers
- Conditions
- Atrial FibrillationVenous Thromboembolism
- Interventions
- Drug: APO-Dabigatran 150mg
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 46
- Registration Number
- NCT04157881
- Locations
- 🇨🇦
The Population Health Research Institute, Hamilton, Ontario, Canada
The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 313
- Registration Number
- NCT04132479
- Locations
- 🇲🇲
Insein General Hospital, Yangon, Myanmar
Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.
- Conditions
- Esophageal Disease
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT04001400
- Locations
- 🇰🇷
Seoul National University Bungdang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT03979248
- Locations
- 🇳🇱
PRA Health Sciences - Netherlands, Groningen, Netherlands
A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Changi General Hospital
- Target Recruit Count
- 252
- Registration Number
- NCT03908619
- Locations
- 🇸🇬
Clinical Trials & Research Unit, Singapore, Singapore
Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication
- Conditions
- Helicobacter GastritisHelicobacter Pylori InfectionHelicobacter-Associated Pyloric Ulcer
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 530
- Registration Number
- NCT03802318
- Locations
- 🇨🇳
Chang-Gung memorial hospital at Keelung, Keelung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.